Welcome to our dedicated page for Transmedics Group news (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on Transmedics Group stock.
TransMedics Group, Inc. reports developments in medical technology for organ transplant therapy, centered on its Organ Care System, or OCS, for preserving and monitoring donor lungs, hearts and livers outside the body. Company updates commonly cover OCS utilization through the National OCS Program, transplant logistics services, aviation fleet capacity, revenue trends and margin drivers.
Recurring news also includes clinical and regulatory disclosures tied to OCS programs and the Controlled Hypothermic Organ Preservation System, tax-accounting updates, material agreements, governance actions and employee equity awards. These developments reflect the company's commercial-stage model in organ preservation, transplant logistics and transplant-service support.
TransMedics (Nasdaq:TMDX) reported second quarter 2026 revenue of $189.9 million, up 21% year over year, driven by higher utilization of its Organ Care System, especially liver and heart via the National OCS Program, and growth in logistics services. Product revenue rose 16% to $111.2 million and service revenue increased 29% to $78.8 million.
Gross margin was 60% versus 61% a year ago. Operating expenses rose to $89.5 million from $60.0 million, reflecting investment in OCS Kidney, Gen 3.0, clinical programs and infrastructure. Income from operations declined to $23.7 million from $36.6 million, while net income fell to $14.7 million, or $0.41 per diluted share, from $34.9 million, or $0.92 per diluted share. Cash stood at $472.7 million on June 30, 2026. The company raised the low end of its 2026 revenue outlook to $737–$757 million, implying 22%–25% growth versus 2025, excluding PAD Aviation revenue. On July 1, 2026, TransMedics completed a strategic investment in PAD Aviation to start building a dedicated organ transport air logistics network in Europe.
TransMedics (Nasdaq: TMDX) reported that on July 29, 2026 it granted non-qualified stock options for an aggregate 18,762 shares and 12,414 restricted stock units to nine new employees as material inducement awards under its Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
The options have a 10-year term, a per-share exercise price of $78.00, and vest 25% after one year with the balance vesting monthly over three years, subject to continued service. RSUs vest 25% on each of the first four anniversaries of employment, also subject to continued service.
TransMedics (Nasdaq: TMDX) announced it will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026. The TransMedics management team is scheduled to present at 2:00 p.m. ET / 1:00 p.m. CT. A live and archived webcast of the fireside chat, along with the company’s standard investor presentation, will be accessible via the Investors section of the TransMedics website.
TransMedics (Nasdaq:TMDX) will release its second quarter 2026 financial results after market close on Tuesday, August 4, 2026. Management will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT with phone and webcast access for investors.
TransMedics Group (Nasdaq:TMDX) completed a strategic investment in PAD Aviation, a Germany-based private aviation operator. The partnership aims to support replication of the OCS NOP model in Europe, expand adoption of OCS perfusion technology, and build a dedicated pan-European organ transplant air and ground logistics network.
TransMedics (Nasdaq:TMDX) granted inducement equity awards under Nasdaq Listing Rule 5635(c)(4) to 14 new employees effective May 19, 2026.
Awards cover 37,367 stock options at a $66.13 exercise price and 24,848 RSUs, including grants to Senior Vice President and General Counsel Matthew S. Forsyth, with multi‑year time-based vesting.
TransMedics (Nasdaq:TMDX) will participate in the William Blair 46th Annual Growth Stock Conference in Chicago on June 2, 2026. Management presents at 2:20 p.m. ET / 1:20 p.m. CT, with live and archived webcasts available on the company’s investor relations website.
TransMedics (Nasdaq: TMDX) reported first quarter 2026 results: revenue $173.9M (up 21% YoY) and net income $7.3M ($0.20 diluted). The company reiterated 2026 revenue guidance of $727M–$757M (20%–25% growth) and held $461.7M in cash as of March 31, 2026.
Operating income and margins declined versus prior year amid higher operating and R&D investments; TransMedics also announced strategic logistics moves, including a PAD Aviation investment and 22 owned aircraft.
TransMedics (Nasdaq: TMDX) entered a definitive agreement to invest in Germany-based PAD Aviation to support creation of a dedicated organ transplant air and ground logistics network across Europe.
The proposed investment aims to replicate TransMedics' U.S. NOP logistics model, support the OCS perfusion platform and clinical services, and expand access to donor organs. Closing is expected later in 2026 and is subject to customary closing and regulatory conditions; financial terms were not disclosed.
TransMedics (Nasdaq: TMDX) unveiled the Controlled Hypothermic Organ Preservation System (CHOPS) at ISHLT 2026 to expand its product portfolio and support control arms in ENHANCE Heart Part B and DENOVO Lung trials.
CHOPS is an active cooling device intended to provide stable, adjustable cold storage. TransMedics will submit an IDE amendment to permit CHOPS as the control arm. The FDA granted full IDE approval for the Next-Generation OCS ENHANCE Heart trial in February 2026 and for the Next-Generation OCS DENOVO Lung trial in January 2026.